KLK3 and prostate cancer: AR is reported to be suppressed by N-Myc in NEPC [51] and the p38MAPK/FOXC2/Zeb1 pathway in prostate cancer stem-like cells (PCSCs), and inhibition of FOXC2 can reduce stem cell properties and restore AR/PSA expression and also sensitivity to docetaxel in DU145 cells [52].